RecruitingPhase 1NCT07215884

Dopamine and Sensorimotor Function in Stuttering


Sponsor

University of California, San Francisco

Enrollment

40 participants

Start Date

Sep 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

  • native speakers of American English
  • for adults who stutter, presence of stuttering will be confirmed, with onset before age 6 years
  • Normal hearing
  • Ages of 18 to 65 years
  • healthy adults without hearing-language difficulties

Exclusion Criteria3

  • self-reported speech-language-hearing difficulties other than stuttering
  • self-reported neurological or psychological problems
  • other medications (drugs that affect dopaminergic system and/or benzodiazepines)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAripiprazole 10 MG

The effects of aripiprazole on stuttering and various behavioral and neural outcomes will be studied compared to placebo.

DRUGPlacebo

Placebo will be compared against aripiprazole for effect on stuttering and various behavioral and neural markers.


Locations(1)

Biomagentic Imaging Lab

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07215884


Related Trials